²¹³Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer

Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1099-1100. doi: 10.1007/s00259-017-3657-9. Epub 2017 Mar 2.

Authors

Mike Sathekge¹, Otto Knoesen², Marian Meckel³, Moshe Modiselle⁴, Mariza Vorster⁴, Sebastian Marx³

Affiliations

¹ Department of Nuclear Medicine, Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa. mike.sathekge@up.ac.za.
² NTP Radioisotopes, The South African Nuclear Energy Corporation, Pelindaba, Pretoria, South Africa.
³ ITG Isotope Technologies Garching GmbH, Garching bei München, Germany.
⁴ Department of Nuclear Medicine, Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa.

No abstract available

Publication types

Case Reports

MeSH terms

Alpha Particles / therapeutic use*
Bismuth / therapeutic use*
Dipeptides / therapeutic use*
Heterocyclic Compounds, 1-Ring / therapeutic use*
Humans
Male
Molecular Targeted Therapy
Neoplasm Metastasis
Prostate-Specific Antigen
Prostatic Neoplasms, Castration-Resistant / pathology*
Prostatic Neoplasms, Castration-Resistant / radiotherapy*
Radioisotopes / therapeutic use*

Substances

Bismuth-213
Dipeptides
Heterocyclic Compounds, 1-Ring
PSMA-617
Radioisotopes
Prostate-Specific Antigen
Bismuth